Warren G. Young, Ph.D. is the key principal in the company, serving as the President and CEO. Dr. Young has more than twenty years of neuroscience imaging hardware and software development experience. While at the University of California, San Diego, his research interest was in the signals of food-based satiety, with early efforts focused on the neurophysiological and neurochemical mechanisms. Surgical and chemical based mechanisms were thought to have a role in controlling hunger and appetite. Following the basic research programs at UCSD, Dr. Young developed a strong interest in the applications of computer hardware and software technology to basic neuroscience research, specifically in the field of neuroanatomy as it applied to investigation into neuropathological mechanisms in several degenerative diseases such as Alzheimer's disease. At the Salk Institute and then at The Scripps Research Institute, projects involving the control of imaging instrumentation and the analysis of microscope images of brain tissue sections proved to be some of the earliest and most powerful forms of computer-controlled microscopy imaging analysis. This work continues to the present day, evolving each generation of the platform application to encompass ever-more-powerful hardware and software technologies applied to discovery programs in neurodegeneration.

The evolution of these imaging platforms lead to the formation in 2000 of a biotech company, Neurome, Inc. in La Jolla, CA. Dr. Young is the co-founder of Neurome whose initial mission as a platform based biotech company was to apply a scaled-up version of his imaging platform to discovery programs focused on neurodegenerative disorders. All of the core imaging technology used in the discovery programs at Neurome was developed by Dr. Young. Partnerships with Elan, Merck, Wyeth, Lilly, La Jolla Pharmaceuticals, ImClone, High Q Foundation, and Brain Cells ensued and Dr. Young was the key negotiator in all of the business deals. From 2000 to 2002, he served as the Chief Technology Officer and from 2002 to 2006, he served as the President and Chief Operating Officer. In 2004, Neurome transitioned into a drug discovery program, using the platforms as an internal research instrument in its own neurodegeneration programs. Dr. Young left the company in early 2006 to continue fueling his strong interest in developing new technologies and utilizing them in nascent applications in biomedical fields.

The field of ophthalmology, particularly that involving anterior-based surgery (cornea, intraocular lens (IOL) implantation, etc) has a strong potential for leveraging advanced imaging technologies. Current surgical techniques utilize fairly staid analog based techniques. Digital imaging has not made an impact in ophthalmic surgery, to date. Due to the nature of the targeted surgical fields, 3D stereoscopic imaging is strongly indicated over monoscopic imaging. Because of these strong attractors and indicators, Dr. Young joined an early stage company, 3D Vision Systems, Inc. of Irvine, CA as the Chief Technology Officer. The mission of 3D Vision Systems is to develop novel 3D stereoscopic imaging solutions for applications in ophthalmic surgery using hardware designed in-house, along with all of the controlling software to move - in real-time - the data from the imaging modules to the stereoscopic monitors used by all of the surgical staff. Prototype units used in human IOL surgeries validated the utility of this digital approach. All of the technology development is managed by Dr. Young. The company is now seeking a Series A round investment. Dr. Young has joined the executive staff in this effort.

Prior to these posts, Dr. Young was at The Scripps Research Institute as a faculty member in the Neuropharmacology Department and as the Director of Neuropharmacology Computing. Working with a department of over 100 members, specialized computer applications in imaging and instrumentation control were developed by his team for use in basic neuroscience research.

Dr. Young received a Ph.D. in Neurosciences from the University of California at San Diego and a B.A. in Physiology and Zoology from Rutgers University at Newark, NJ. He sits as a Director on the boards of Neurome, Inc. and of ReWire Therapies LTD of West Perth, Australia. He is serves as an Advisory Board Member to the Huntington's Disease Society of America, San Diego Chapter and volunteers a significant amount of his time as the head coach of the Science Olympiad program at his son's Westview High School Program, competing at the regional, state and national level. He currently lives in San Diego with his wife and children.